Elite in Synovial Sarcoma

Dr. George D. Demetri

Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Elite in Synovial Sarcoma
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

George Demetri is an Oncologist in Boston, Massachusetts. Dr. Demetri is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Liposarcoma, and Synovial Sarcoma. Dr. Demetri is currently accepting new patients.

His clinical research consists of co-authoring 164 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 4 clinical trials in the study of Synovial Sarcoma.

Specialties
Oncology
Licenses
Internal Medicine in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Tufts
  • HMO
View 1 Less Insurance Carrier -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Biological
Study Phase: Phase 1
Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma or Rhabdomyosarcoma Following Failure of Prior Chemotherapy
Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma or Rhabdomyosarcoma Following Failure of Prior Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Olaparib, Temozolomide, Irinotecan
Study Phase: Phase 1
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Enrollment Status: Terminated
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drugs: Tazemetostat, Doxorubicin
Study Phase: Phase 3
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Genetic
Study Phase: Phase 2
An Open-Label, Randomised, Multi-Centre, Phase II Study to Investigate the Safety and Efficacy of AT13387, Either as Monotherapy or in Combination With Imatinib, in Patients With Unresectable and/or Metastatic Malignant GIST Whose Tumour Has Progressed Following Treatment With a Maximum of Three Tyrosine Kinase Inhibitors
An Open-Label, Randomised, Multi-Centre, Phase II Study to Investigate the Safety and Efficacy of AT13387, Either as Monotherapy or in Combination With Imatinib, in Patients With Unresectable and/or Metastatic Malignant GIST Whose Tumour Has Progressed Following Treatment With a Maximum of Three Tyrosine Kinase Inhibitors
Enrollment Status: Completed
Publish Date: August 02, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 30, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Dose Finding Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Patients With Advanced or Malignancies
A Phase I Dose Finding Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Patients With Advanced or Malignancies
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

164 Total Publications

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.
Journal: Future oncology (London, England)
Published: February 11, 2025
Similar Doctors
Elite in Synovial Sarcoma
Dr. Edwin Choy
Hematology Oncology | Oncology
Elite in Synovial Sarcoma
Dr. Edwin Choy
Hematology Oncology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edwin Choy is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Choy is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Osteosarcoma, and Synovial Sarcoma. Dr. Choy is currently accepting new patients.

Elite in Synovial Sarcoma
Dr. Gregory Cote
Hematology Oncology | Hematology | Oncology
Elite in Synovial Sarcoma
Dr. Gregory Cote
Hematology Oncology | Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gregory Cote is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Cote is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Chordoma, Epithelioid Sarcoma, Synovial Sarcoma, and Tissue Biopsy.

Elite in Synovial Sarcoma
Dr. Michael J. Nathenson
Oncology
Elite in Synovial Sarcoma
Dr. Michael J. Nathenson
Oncology
450 Brookline Ave, Dana-farber Cancer Institute, 
Boston, MA 
 (0.1 miles away)
617-582-9396
Languages Spoken:
English

Michael Nathenson is an Oncologist in Boston, Massachusetts. Dr. Nathenson is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Salpingo-Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Demetri's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile